Kalaris Therapeutics Inc Q2 Operating Income USD -12.386 Million Vs. IBES Estimate USD -12.5 Million

KLRS•2026-08-11

Net income

Q2 net income was USD -11.515 million versus the IBES estimate of USD -12.1 million.

Q2 operating income and expenses

Aug. 11 (Reuters) - Kalaris Therapeutics Inc reported second-quarter operating income of USD -12.386 million versus the IBES estimate of USD -12.5 million.

The company said Q2 operating expenses were USD 12.386 million.

Kalaris Therapeutics Inc Q2 Operating Income USD -12.386 Million Vs. IBES Estimate USD -12.5 Million

Net income

Q2 operating income and expenses

Related News

Sweden's Eco Wave Power H1 net loss narrows on cost discipline

Astrotech unit Lunar Power and Light plans commercial lunar electric utility network

Bicara Therapeutics Appoints Ryan Cohlhepp As President & CEO Effective January 2027

Varex Imaging <VREX.O>: Oppenheimer cuts to perform from outperform

Gold Fields sees H1 HEPS at US$1.98-US$2.18, up 72%-90%